Skip to content
2000
Volume 20, Issue 4
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a serious adverse reaction that occurs weeks after the onset of drug exposure. DRESS syndrome is commonly associated with antiseizure drugs, sulfa drugs, and antibiotics.

Case Presentation

This was a case report of a 20-year-old female who suffered from DRESS due to vancomycin with symptoms similar to the Redman syndrome. The patient was a case of Infective endocarditis due to methicillin-resistant (MRSA), and vancomycin was intravenously administered. On the 18th day, during the administration of vancomycin, the patient developed sudden severe flushing over the face and trunk. The offending drug was suspended and treated with antihistamines in view of Redman syndrome. Later, the patient developed uncontrolled fever, desquamating rash all over the body, severe pruritis, and eosinophilia. On applying the RegiScar score, a probable case of DRESS was diagnosed. The patient was managed symptomatically and discharged.

Discussion

The clinical presentation of DRESS includes skin rash, fever, eosinophilia, and organ involvement. But, in this case, there was a varied initial presentation of DRESS with severe flushing, which mimics the Redman syndrome due to vancomycin. Difficulty in establishing organ involvement remained a challenge in diagnosing DRESS.

Conclusion

DRESS can have a varied clinical presentation. Careful monitoring of all vital parameters is important in preventing the misdiagnosis of DRESS syndrome.

Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863333025241113055751
2025-01-07
2025-08-21
Loading full text...

Full text loading...

References

  1. HusainZ. ReddyB.Y. SchwartzR.A. DRESS syndrome: Part I. Clinical perspectives.J. Am. Acad. Dermatol.2013685693.e1693.e1410.1016/j.jaad.2013.01.033 23602182
    [Google Scholar]
  2. ChoudharyS. McLeodM. TorchiaD. RomanelliP. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.J. Clin. Aesthet. Dermatol.2013663137 23882307
    [Google Scholar]
  3. KonvinseK.C. TrubianoJ.A. PavlosR. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.J. Allergy Clin. Immunol.2019144118319210.1016/j.jaci.2019.01.045 30776417
    [Google Scholar]
  4. CardonesA.R. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.Clin. Dermatol.202038670271110.1016/j.clindermatol.2020.06.008 33341203
    [Google Scholar]
  5. PeyrièreH. DereureO. BretonH. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist?Br. J. Dermatol.2006155242242810.1111/j.1365‑2133.2006.07284.x 16882184
    [Google Scholar]
  6. KrantzM.S. PhillipsE.J. Drug reaction with eosinophilia and systemic symptoms.JAMA Dermatol.2023159334810.1001/jamadermatol.2022.4519 36630118
    [Google Scholar]
  7. KardaunS.H. SekulaP. Valeyrie-AllanoreL. Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.Br. J. Dermatol.201316951071108010.1111/bjd.12501 23855313
    [Google Scholar]
  8. ChenC.B. HungW.K. WangC.W. LeeC.C. HungS.I. ChungW.H. Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: An updated review.Front. Med. (Lausanne)202310118793710.3389/fmed.2023.1187937 37457584
    [Google Scholar]
  9. ChungK.B. HwangJ.H. KimD. A case of vancomycin-induced drug reaction with eosinophilia, systemic symptoms and multiorgan involvement proven using lymphocyte transformation test.Ann. Dermatol.202335214014510.5021/ad.20.341 37041708
    [Google Scholar]
  10. SasidharanpillaiS. AjithkumarK. JishnaP. RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DiHS): A comparative analysis.Indian Dermatol. Online J.2022131404510.4103/idoj.idoj_196_21 35198466
    [Google Scholar]
  11. Del Pozzo-MagañaB.R. RiederM.J. Garcia-BournissenF. Lazo-LangnerA. Drug reaction with eosinophilia and systemic symptoms (DRESS): A tertiary care centre retrospective study.Br. J. Clin. Pharmacol.20228894134414110.1111/bcp.15354 35421262
    [Google Scholar]
  12. CardosoCS VieiraAM OliveiraAP DRESS syndrome: A case report and literature review.BMJ Case Rep20112011jun03 1bcr022011389810.1136/bcr.02.2011.3898 22693316
    [Google Scholar]
  13. ManieriE. DondiA. NeriI. LanariM. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: A narrative review.Front. Med. (Lausanne)202310110834510.3389/fmed.2023.1108345 37575981
    [Google Scholar]
  14. DeA. RajagopalanM. SardaA. DasS. BiswasP. Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature.Indian J. Dermatol.2018631304010.4103/ijd.IJD_582_17 29527023
    [Google Scholar]
  15. CalleA.M. AguirreN. ArdilaJ.C. Cardona VillaR. DRESS syndrome: A literature review and treatment algorithm.World Allergy Organ. J.202316310067310.1016/j.waojou.2022.100673 37082745
    [Google Scholar]
  16. KulkarniM.P. ChintaS. SosaF. NasrR. KellyP. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome due to vancomycin.Cureus2022146e2621910.7759/cureus.26219 35911307
    [Google Scholar]
  17. KardaunS.H. SidoroffA. Valeyrie-AllanoreL. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist?Br. J. Dermatol.2007156360961110.1111/j.1365‑2133.2006.07704.x 17300272
    [Google Scholar]
  18. PatelS. PreussC.V. BerniceF. Vancomycin.Treasure Island, FLStatPearls Publishing2024 29083794
    [Google Scholar]
  19. RubinsteinE. KeynanY. Vancomycin revisited - 60 years later.Front. Public Health2014221710.3389/fpubh.2014.00217 25401098
    [Google Scholar]
  20. GanetskyA. HanJ.H. HughesM.E. Oral vancomycin prophylaxis is highly effective in preventing clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.Clin. Infect. Dis.201968122003200910.1093/cid/ciy822 30256954
    [Google Scholar]
  21. AnS.Y. HwangE.K. KimJ.H. Vancomycin-associated spontaneous cutaneous adverse drug reactions.Allergy Asthma Immunol. Res.20113319419810.4168/aair.2011.3.3.194 21738885
    [Google Scholar]
  22. BrunieraF.R. FerreiraF.M. SaviolliL.R.M. The use of vancomycin with its therapeutic and adverse effects: A review.Eur. Rev. Med. Pharmacol. Sci.2015194694700 25753888
    [Google Scholar]
  23. WallaceM.R. MascolaJ.R. OldfieldE.C. Red man syndrome: Incidence, etiology, and prophylaxis.J. Infect. Dis.199116461180118510.1093/infdis/164.6.1180 1955716
    [Google Scholar]
  24. SivagnanamS. DeleuD. Red man syndrome.Crit. Care20037211912010.1186/cc1871 12720556
    [Google Scholar]
  25. YuanK. AwanK.S. LongJ. Vancomycin-induced drug rash with eosinophilia and systemic symptoms (DRESS).BMJ Case Rep.2020132e23230210.1136/bcr‑2019‑232302 32024716
    [Google Scholar]
  26. BacalA. HumphreyT. YousufT. Vancomycin-induced drug rash with eosinophilia and systemic symptoms.J. Med. Cases20156520120410.14740/jmc2103w
    [Google Scholar]
  27. HewitsonL.J. Vancomycin induced DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) in a patient with tricuspid endocarditis.BMJ Case Rep.2019129e22959010.1136/bcr‑2019‑229590 31527200
    [Google Scholar]
  28. PalA. SenS. BiswasA. NaserS.M. TripathiS.K. A rare case of DRESS syndrome caused by vancomycin.J. Acute Med.201553747610.1016/j.jacme.2015.06.001
    [Google Scholar]
  29. WilcoxO. HassaneinM. ArmstrongJ. KassisN. Case report: Atypical presentation of vancomycin induced DRESS syndrome: A case report and review of the literature.BMC Pulm. Med.201717121710.1186/s12890‑017‑0564‑6 29282040
    [Google Scholar]
  30. RoyS. GoswamyV.P. BarssoumK.N. RaiD. Vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome masquerading as elusive sepsis.Case Reports Immunol.201920191510.1155/2019/1625010 31093389
    [Google Scholar]
  31. Bilbao-MeseguerI. Rodríguez-GascónA. BarrasaH. IslaA. SolinísM.Á. Augmented renal clearance in critically ill patients: A systematic review.Clin. Pharmacokinet.20185791107112110.1007/s40262‑018‑0636‑7 29441476
    [Google Scholar]
  32. MorbitzerK.A. RhoneyD.H. DehneK.A. JordanJ.D. Enhanced renal clearance and impact on vancomycin pharmacokinetic parameters in patients with hemorrhagic stroke.J. Intensive Care2019715110.1186/s40560‑019‑0408‑y 31832200
    [Google Scholar]
  33. BaptistaJ.P. SousaE. MartinsP.J. PimentelJ.M. Augmented renal clearance in septic patients and implications for vancomycin optimisation.Int. J. Antimicrob. Agents201239542042310.1016/j.ijantimicag.2011.12.011 22386742
    [Google Scholar]
  34. ZhaoJ. FanY. YangM. Association between augmented renal clearance and inadequate vancomycin pharmacokinetic/pharmacodynamic targets in chinese adult patients: A prospective observational study.Antibiotics (Basel)202211783710.3390/antibiotics11070837 35884091
    [Google Scholar]
  35. ChuY. LuoY. QuL. ZhaoC. JiangM. Application of vancomycin in patients with varying renal function, especially those with augmented renal clearance.Pharm. Biol.201654122802280610.1080/13880209.2016.1183684 27251880
    [Google Scholar]
  36. ShuklaA.K. JhajR. MisraS. AhmedS.N. NandaM. ChaudharyD. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions.J. Family Med. Prim. Care20211093303330810.4103/jfmpc.jfmpc_831_21 34760748
    [Google Scholar]
  37. NaranjoC.A. BustoU. SellersE.M. A method for estimating the probability of adverse drug reactions.Clin. Pharmacol. Ther.198130223924510.1038/clpt.1981.154 7249508
    [Google Scholar]
  38. PetrovaG. StoimenovaA. DimitrovaM. KamushevaM. PetrovaD. GeorgievO. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy.SAGE Open Med.20175205031211769040410.1177/2050312117690404 28228952
    [Google Scholar]
  39. SchumockG.T. ThorntonJ.P. Focusing on the preventability of adverse drug reactions.Hosp. Pharm.1992276538 10118597
    [Google Scholar]
/content/journals/cds/10.2174/0115748863333025241113055751
Loading
/content/journals/cds/10.2174/0115748863333025241113055751
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test